Chardan Capital Maintains Buy on Silence Therapeutics, Raises Price Target to $55
SILENCE THERAPEUTICS PLC SPON ADS EACH REP 3 ORD SHS -0.06% Pre
SILENCE THERAPEUTICS PLC SPON ADS EACH REP 3 ORD SHS SLN | 18.07 18.07 | -0.06% 0.00% Pre |
Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:
SLN) with a Buy and raises the price target from $42 to $55.